特拉万星盐酸盐 | 560130-42-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 特拉万星盐酸盐
• 中文别名: 盐酸特拉万星；泰拉万星盐酸盐
• 英文名称: Telavancin Hydrochloride
• 英文别名: (1S,2R,18R,19R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-[2-(decylamino)ethylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-36-[(phosphonomethylamino)methyl]-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid;hydrochloride
• CAS: 560130-42-9
• 化学式: C80H107Cl3N11O27P
• 分子量: 1792.1
• InChiKey: GSSIWSIRBWAZHG-ACOPVEIWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.11
• 重原子数：
  122
• 可旋转键数：
  30
• 环数：
  12.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  598
• 氢给体数：
  24
• 氢受体数：
  31

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：特拉万星有93%与血浆蛋白结合，且口服吸收不良，因此不太可能进入婴儿的血液或对哺乳婴儿产生任何不良反应。如果母亲需要特拉万星，这不是停止哺乳的理由。监测婴儿可能的胃肠道反应，例如腹泻、呕吐和念珠菌病（例如，鹅口疮、尿布疹）。 ◉ 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 ◉ 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:Telavancin is 93% plasma protein bound and is poorly absorbed orally, so it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. If telavancin is required by the mother, it is not a reason to discontinue breastfeeding. Monitor the infant for possible effects on the gastrointestinal tract, such as diarrhea, vomiting, and candidiasis (e.g., thrush, diaper rash). ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

反应信息

• 作为产物：
  描述：

  生成 特拉万星盐酸盐
  参考文献：
  名称：

  [EN] PROCESS FOR THE SYNTHESIS OF TELAVANCIN, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AS WELL AS AN N-PROTECTED IMINE-DERIVATIVE OF TELAVANCIN
  [FR] PROCÉDÉ DE SYNTHÈSE DE TÉLAVANCINE ET DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET DÉRIVÉ IMINE N-PROTÉGÉ DE TÉLAVANCINE

  摘要：

  本发明涉及一种制备特拉凡芹的过程，或其药学上可接受的盐，其中该过程包括烷基化万古霉素，以提供N-保护基-癸基氨基乙基万古霉素亚胺，随后进行氨基甲基化以获得N-保护基-特拉凡芹亚胺，然后将其还原和去保护以提供特拉凡芹，或其药学上可接受的盐。另一实施例涉及在本发明过程中形成的N-保护基-特拉凡芹亚胺。

  公开号：

  WO2013034676A1

文献信息

• [EN] PROCESS FOR PREPARING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES<br/>[FR] PROCEDES DE PREPARATION DE DERIVES DU GLYCOPEPTIDE PHOSPHONATE
  申请人：THERAVANCE INC

  公开号：WO2003029270A2

  公开（公告）日：2003-04-10

  Disclosed are processes for preparing glycopeptide phosphonate derivatives having an amino-containing side chain. Several of the process steps are conducted in a single reaction vessel without isolation of intermediate reaction products, thereby generating less waste and improving the overall efficiency and yield of the process.

  本发明涉及制备具有含氨基侧链的糖肽磷酸酯衍生物的过程。其中，几个步骤在单个反应容器中进行，无需分离中间反应产物，从而产生更少的废物，提高了整个过程的效率和产率。
• Process for preparing glycopeptide phosphonate derivatives
  申请人：Leadbetter Michael R.

  公开号：US06979723B2

  公开（公告）日：2005-12-27

  Disclosed are processes for preparing glycopeptide phosphonate derivatives having an amino-containing side chain. Several of the process steps are conducted in a single reaction vessel without isolation of intermediate reaction products, thereby generating less waste and improving the overall efficiency and yield of the process.

  本发明涉及制备具有含氨基侧链的糖肽膦酸酯衍生物的过程。其中，几个步骤在单一反应容器中进行，而无需分离中间反应产物，从而产生更少的废物，提高了整个过程的效率和产量。
• [EN] GLYCOPEPTIDE PHOSPHONATE DERIVATIVES<br/>[FR] DERIVES PHOSPHONATES DE GLYCOPEPTIDES
  申请人：ADVANCED MEDICINE INC

  公开号：WO2001098328A2

  公开（公告）日：2001-12-27

  Disclosed are derivatives of glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.

  本发明涉及一种糖肽衍生物，其被一个或多个取代基所取代，每个取代基包含一个或多个膦酸基团，并且包含这种糖肽衍生物的药物组合物。所述的糖肽衍生物可用作抗菌剂。
• Glycopeptide phosphonate derivatives
  申请人：Theravance, Inc.

  公开号：US06635618B2

  公开（公告）日：2003-10-21

  Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.

  本发明涉及一种含有一个或多个取代基的糖肽，每个取代基包含一个或多个膦酸基团；以及包含这样的糖肽衍生物的制药组合物。所述糖肽衍生物可用作抗菌剂。
• [EN] PROCESS FOR PURIFYING GLYCOPEPTIDE PHOSPOHONATE DERIVATIVES<br/>[FR] PROCEDE DE PURIFICATION DE DERIVES PHOSPHONATES DE GLYCOPEPTIDES
  申请人：THERAVANCE INC

  公开号：WO2003018608A2

  公开（公告）日：2003-03-06

  Disclosed are methods of purifying glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups that are useful as antibacterial agents. The methods include contacting a solution of the glycopeptide derivatives with a polystyrene-containing resin, eluting the resin with an aqueous solution, and isolating the purified glycopeptide derivative.

  本发明涉及一种用于纯化糖基肽的方法，该糖基肽被替代为一个或多个取代基，每个取代基包含一个或多个磷酸酯基团，该糖基肽可用作抗菌剂。该方法包括将糖基肽衍生物的溶液与含有聚苯乙烯的树脂接触，用水溶液洗脱树脂，并分离纯化的糖基肽衍生物。